Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial

Bron
Gynecologic oncology - ISSN 0090-8258-191 (2024) p. 275-286
Auteur(s)
    Emiel A. De Jaeghere, Hannelore Hamerlinck, Sandra Tuyaerts, Lien Lippens, An M.T. Van Nuffel, Regina Baiden-Amissah, Peter Vuylsteke, Stephanie Henry, Xuan Bich Trinh, Peter André Van Dam, Sandrine Aspeslagh, Alex De Caluwe, Eline Naert, Diether Lambrechts, An Hendrix, Olivier De Wever, Koen Van de Vijver, Frederic Amant, Katrien Vandecasteel, Bruno Verhasselt, Hannelore G. Denys

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study

Bron
Cancer immunology and immunotherapy - ISSN 0340-7004-72:2 (2023) p. 475-491
Auteur(s)
    Emiel A. De Jaeghere, Sandra Tuyaerts, An M.T. Van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens, Peter Vuylsteke, Stephanie Henry, Xuan Bich Trinh, Peter André Van Dam, Sandrine Aspeslagh, Alex De Caluwe, Eline Naert, Diether Lambrechts, An Hendrix, Olivier De Wever, Koen Van de Vijver, Frederic Amant, Katrien Vandecasteele, Hannelore G. Denys